

# A Survey of Medical Oncologist's Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with Vectibix (20160258)

**First published:** 26/04/2017

**Last updated:** 02/07/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS18060

---

### Study ID

21200

---

### DARWIN EU® study

No

---

### Study countries

 United States

---

## Study description

The study population consisted of practicing oncologists in the United States who treat patients with mCRC. Oncologists were recruited from a national database through a third party panel provider, M3 Global Research®. M3 Global Research® has access to over two million physicians and one million health care professionals globally for participation in both qualitative and quantitative studies. The oncologists were sampled at random and then stratified by size of institution, type of institution (academic cancer centers and community hospitals) and region within the United States to assess the following objectives:

- Describe oncologist's opinions regarding the management of dermatologic toxicities, including opinions regarding the timing of rash management in relation to the initiation of treatment with Vectibix and the manner in which the rash is managed.
- Describe oncologist's perceptions about the manner in which they preparing their patients for the possibility of developing dermatologic toxicities.

---

## Study status

Finalised

# Research institutions and networks

## Institutions

Amgen



United States

**First published:** 01/02/2024

**Last updated:** 27/03/2026

Institution

## Contact details

### Study institution contact

Global Development Leader Amgen Inc.  
medinfo@amgen.com

Study contact

[medinfo@amgen.com](mailto:medinfo@amgen.com)

### Primary lead investigator

Global Development Leader Amgen Inc.

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 15/07/2016

Actual: 15/07/2016

---

### Study start date

Planned: 09/09/2016

Actual: 09/09/2016

---

### Data analysis start date

Planned: 24/09/2016

Actual: 18/10/2016

---

### Date of final study report

Planned: 18/10/2016

Actual: 18/10/2016

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Amgen

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study topic:**

Disease /health condition

Human medicinal product

---

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Other

**If 'other', further details on the scope of the study**

Physician perception and opinion regarding EGFR rash among mCRC patients treated with Vectibix

**Data collection methods:**

Primary data collection

---

**Main study objective:**

Describe oncologist's opinions regarding the management of dermatologic toxicities, including opinions regarding the timing of rash management in relation to the initiation of treatment with Vectibix and the manner in which the rash is managed. Describe oncologist's perceptions about the manner in which they preparing their patients for the possibility of developing dermatologic toxicities.

## Study Design

**Non-interventional study design**

Other

---

**Non-interventional study design, other**

Survey

## Study drug and medical condition

**Medicinal product name, other**

Vetibix

---

## **Medical condition to be studied**

Rash

## Population studied

### **Short description of the study population**

Oncologists (i.e.: licensed and practicing oncologist) were recruited from the M3 Global Research database who had treated at least three new or continuing metastatic colorectal cancer patients with panitumumab in the last year.

---

### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Special population of interest**

Other

---

### **Special population of interest, other**

Colorectal cancer patients

---

### **Estimated number of subjects**

250

## Study design details

### **Data analysis plan**

The proportion of patients who select each answer within a survey question will be summarized and confidence intervals will be estimated as the estimated proportion  $\pm 1.96$  multiplied by the estimated standard error. We will stratify our analysis by the following variables: • Primary hospital affiliation (academic/university hospital, community non-teaching hospital, and community teaching hospital). • Size of practice setting (>20 doctors, 6-20 doctors, <5 doctors, solo practice). • Number of new or continuing metastatic colorectal cancer patients the oncologist personally treated (stratify at the median number of patients reported by the participating oncologists).

## Documents

### Study results

[20160258\\_ORSR\\_Final\\_Abstract.pdf](#) (74.49 KB)

---

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

Other

---

**Data sources (types), other**

Physician survey

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

Unknown